AE Wealth Management LLC decreased its position in shares of iShares Biotechnology ETF (NASDAQ:IBB – Get Rating) by 11.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 24,522 shares of the financial services provider’s stock after selling 3,078 shares during the period. AE Wealth Management LLC’s holdings in iShares Biotechnology ETF were worth $3,219,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in IBB. Macroview Investment Management LLC purchased a new stake in iShares Biotechnology ETF during the 4th quarter worth $26,000. Armstrong Advisory Group Inc. acquired a new position in iShares Biotechnology ETF during the 4th quarter worth $26,000. Accurate Wealth Management LLC acquired a new position in iShares Biotechnology ETF during the 4th quarter worth $31,000. SYM FINANCIAL Corp grew its holdings in iShares Biotechnology ETF by 86.6% during the 4th quarter. SYM FINANCIAL Corp now owns 237 shares of the financial services provider’s stock worth $31,000 after acquiring an additional 110 shares in the last quarter. Finally, Phillips Financial Management LLC acquired a new position in iShares Biotechnology ETF during the 3rd quarter worth $32,000. Hedge funds and other institutional investors own 58.02% of the company’s stock.
iShares Biotechnology ETF Price Performance
Shares of IBB stock opened at $132.66 on Wednesday. iShares Biotechnology ETF has a 1-year low of $104.29 and a 1-year high of $138.74. The firm has a fifty day moving average of $128.28 and a two-hundred day moving average of $130.98.
About iShares Biotechnology ETF
iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.
Read More
- Get a free copy of the StockNews.com research report on iShares Biotechnology ETF (IBB)
- Gamida Cell Stock Jumps Over 100% on FDA Approval
- Insiders Buy EasyJet, Regularly And Repeatedly
- Bank of America Beats Earnings, Renews Investor Upside Potential
- The Analysts See A Bright Future For Sunrun
- J.B. Hunt: Economic Contraction And A Buying Opportunity
Receive News & Ratings for iShares Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.
